Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, ...

Over 35 years ago, a group led by Dr. Lowy contributed to the early studies that identified RAS as a cancer-causing gene and helped explain how it promotes tumor growth. In this new study, the ...

Over 35 years ago, a group led by Dr. Lowy contributed to the early studies that identified RAS as a cancer-causing gene and ...

It causes mutations in the p53 tumor-suppressor gene as well as ras mutations ... They state, "In lung cancer p53 mutations have been found in 56% of tissue samples, and in colorectal, esophageal ...

For instance, growth-promoting genes, such as the gene for the signaling protein Ras, are among those most commonly mutated in cancer cells, becoming super-active and producing cells that are too ...

There is therefore an urgent need for the development and testing of novel agents targeting pathways thought to be involved in the pathogenesis of breast cancer. Aberrant activation of the Ras/Raf ...

Historically, scientists in the division were the first to make the ground-breaking discovery of the mechanism by which the RAS gene – one of the most commonly activated genes in cancer – causes cells ...

Although many of the genes involved in cancer have now been identified ... small GTPase proteins and are mutated in lung adenocarcinoma and in the germline of “Ras-opathy” patients. Although KRAS has ...

“Colorectal-cancer researchers have waited nearly a ... namely those who have a non-mutated version of the RAS gene, panitumumab or bevacizumab combined with chemotherapy are treatment options.